rdoe_global.search

Expand your toolbox for quality mRNA manufacturing with SP6 RNA Polymerase

Starting guidelines for the use of SP6 RNA Polymerase for mRNA synthesis

In vitro synthesis of mRNA molecules is a widely used laboratory procedure that is central to RNA research and for the development of therapeutic applications. Although already decades in development, mRNA was first validated as new drug class with the approval of mRNA COVID-19 vaccines. mRNA is now being considered for diverse applications like protein replacement, cell reprogramming, and gene editing. Individual constructs and intended uses require a tailored manufacturing process. Moving forward, expanded tool-box to produce mRNA will be needed.

In response to customer requests, we now added SP6 RNA Polymerase in a GMP Grade and fit-for-purpose format to our portfolio. This expands options in mRNA manufacturing for our customers. Here we present some starting guidelines for the use of SP6 RNA Polymerase.

Contact Us

Related pages

Overview

Synthesis of mRNA through in vitro transcription (IVT) utilizes a diverse mix of enzymes, proteins,  and ribonucleotides. However, RNA polymerase is the main driver of the reaction to produce mRNA. In simple terms, mRNA synthesis starts when an RNA polymerase recognizes and binds to a highly specific promoter sequence encoded in the DNA template.  This is followed by the elongation of the mRNA strand through the incorporation of ribonucleotides by the RNA polymerase. 

While T7 RNA polymerase is a popular choice for mRNA production (Comirnaty by Pfizer/BioNTech and SpikeVax by Moderna1), other polymerases also work well for mRNA synthesis. SP6 RNA Polymerase is commonly used in molecular biology research along with T7 and T3 RNA polymerases.  

As a starting point, the following is a first technical guidance to test SP6 RNA Polymerase for in vitro synthesis of mRNA.

Introduction 

SP6 RNA polymerase is similar to T7 RNA polymerase in that both are single subunit enzymes and do not require any other additional transcription factors to function. Both enzymes also provide stringent promoter specificity and very high efficiency.2-5  Where they differ, however, is in their unique promoter sites. (Fig. 1) That difference expands options in mRNA synthesis. For example, SP 6 prefers the sequence 5'GAAGA at the start site while T7 RNA polymerase prefers  5'GGGAG.7

promoter sequences

Fig.1:  Comparison of the promoter sequences for T7 and SP6 RNA Polymerase. 

Both promoters share a core sequence that extends from -7 to +1. This region may play a common function in promoter function. They diverge in the region from -8 to -12, suggesting that promoter-specific contacts are being made in this region. By convention, the nontemplate strand is presented.6

Follow these technical guidelines to test if  SP6 RNA Polymerase is a good  fit for your specific template and in vitro transcription process (technical guidance for  T7 RNA Polymerase).8

General guidelines for reaction set up


Multiple buffer options give good overall yield with different constructs

In our experiments, SP6 RNA Polymerase provided good yields using using either Tris or HEPES-based IVT reaction buffers (Fig 2).  Similar observations are reported in the literature. Combined with high-capacity buffers that maintain the pH throughout the reaction, SP6 RNA Polymerase achieves maximum yield in the IVT reaction. The optimal reported pH range is between pH 7.0 and 8.5.2,9

Hepes

Fig.2:  Comparable yields of the Testing the IVT reaction in HEPES and Tris buffer systems forusing two different plasmid constructs (Data on file at Roche: Latta, Application Lab, May 2023)

Optimization of ribonucleotide and Mg2+ concentration for yield

Total ribonucleotide and magnesium concentrations have the most significant impact on the RNA yield. In our experiments, a 1:1 ratio of magnesium to total ribonucleotide concentration showed the greatest yields, as long as the total ribonucleotide concentration did not exceed 20 mM (Fig. 3). These results differ from T7 RNA polymerase, which tolerates towards higher ribonucleotide and magnesium concentrations of up to 40 mM.9

 

ribonucleotide & magnesium concentration

Fig.3: Optimal titration of the Mg2+/ribonucleotide concentration in the IVT reaction. Mg2+ and total rNTP concentrations varied between titrations experiments but were kept at a constant ratio of 1:1 for a given experiment. (Data on file at Roche: Latta, Application Lab, May 2023).

SP6 enzyme concentration has moderate influence on yield 

SP6 RNA Polymerase showed robust performance even at low enzyme concentration, under optimized conditions for other factors like ribonucleotide: magnesium ratio and template concentration. Increasing the enzyme concentration improved performance slightly for the 2.2Kb construct, but optimization with higher enzyme concentration might be crucial for longer mRNA transcripts.

 

Enzyme volume per reaction

Fig.4: A moderate influence of SP6 Polymerase concentratino on the IVT reaction yield (Data on file at Roche: Latta, Application Lab, May 2023).

Experimental conditions

The reaction mix used in the described experiments consisted of 500 ng DNA template of a linearized plasmid, 1 μl SP6 RNA polymerase (CustomBiotech 09959513103), 1 μl pyrophosphatase (CustomBiotech 08140677103), 20 U RNase inhibitor (CustomBiotech 09537643103), 2 μl reaction buffer, and RNase-free water to a final volume of 20 μl. The reaction buffer was prepared from a 10X transcription buffer master mix.10X Tris reaction buffer: 400 mM Tris-HCl, 20 mM spermidine,100 mM DTT, pH 7.9 OR 10X HEPES reaction Buffer: 1 M HEPES-KOH, 20 mM Spermidine, 400 mM DTT, pH 7.5.

The reaction was incubated for 1 h at 37°C. RNA was subsequently purified using the High Pure FFPET RNA Isolation Kit (Mat # 06650775001, sold by Roche Molecular Systems; www. lifescience.roche.com), including proteinase K digestion and DNase I treatment according to the manufacturer‘s instructions. Experiments were performed in triplicates. Subsequently, the resulting RNA was analyzed using the Agilent® Bioanalyzer and quantified using a UV/Vis spectrophotometer at 260 nm (NanoDrop™). Experiment-specific adaptations are mentioned in the respective figure descriptions. Experiments shown in figures 3 and 4 were performed in HEPES buffer with a 2.2 kb mRNA generating template construct.
 

Key takeaways

When working with SP6 RNA Polymerase, some components of the IVT reaction - buffers, RNAse inhibitor and pyrophosphatase concentrations - can be used in similar amounts as in T7 RNA polymerase reactions.

Optimization of the total ribonucleotide and magnesium concentrations seems to be a critical factor for SP6 RNA Polymerase. The enzyme is sensitive to higher concentrations of ribonucleotide: magnesium. 

Use these starting guidelines to determine if  SP6 RNA Polymerase is a good alternative for your specific template and optimize your process.

Regulatory disclaimer
 For further processing into medical devices, IVD and pharmaceutical products only.


Warranty limitation
 It is the sole responsibility of the customer to determine the suitability of all raw materials, products and components in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements. Roche makes no representations or warranties of any kind regarding the Product, express or implied, other than those expressly set forth in the terms and conditions of sale (if any), and disclaims all implied or statutory warranties including warranty of merchantability and fitness for a particular purpose.

 

Legal note
The Product SP6 RNA Polymerase, rec., GMP Grade, AOF is provided by ROCHE for further processing into medical devices, IVD and pharmaceutical products only, re-sale of the Product alone is not permitted. ROCHE does not recommend to the purchaser or the end users of the Product any particular application, methodology and/or protocol for further processing or the use of the Product, respectively. The Product is provided without warranty of merchantability or fitness for a particular purpose. The sale of the Product does not exhaust or grant any rights under a patent, copyright, trademark or other intellectual property right owned or controlled by a third party including any company of the F. Hoffmann - La Roche AG group of companies. For clarity, the sale of the Product does not convey any right, expressly or implied, to use the Product under a third-party-owned patent, copyright, trademark or other intellectual property right. Depending on the particular use of the Product, it may be necessary to obtain a separate license or licenses from one or more third parties for which the purchaser - and not ROCHE - is responsible.

References

  1. Kis, Z., Kontoravdi, C., Dey, A. K., Shattock, R. & Shah, N. Rapid development and deployment of high‐volume vaccines for pandemic response. J Adv Manuf Process 2, e10060 (2020).
  2. Butler, E. T. & Chamberlin, M. J. Bacteriophage SP6-specific RNA polymerase. I. Isolation and characterization of the enzyme. Journal of Biological Chemistry 257, 5772–5778 (1982).
  3. Chamberlin, M. & Ring, J. Characterization of T7-specific Ribonucleic Acid Polymerase. Journal of Biological Chemistry 248, 2235–2244 (1973).
  4. Lee, S. S. & Kang, C. Two base pairs at -9 and -8 distinguish between the bacteriophage T7 and SP6 promoters. Journal of Biological Chemistry 268, 19299–19304 (1993).
  5. Kotani, H., Ishizaki, Y., Hiraoka, N. & Obayashi, A. Nucleotide sequence and expression of the cloned gene of bacteriophage SP6 RNA polymerase. Nucleic Acids Res 15, 2653–2664 (1987).
  6. Jorgensen, E. D., Durbin, R. K., Risman, S. S. & McAllister, W. T. Specific contacts between the bacteriophage T3, T7, and SP6 RNA polymerases and their promoters. Journal of Biological Chemistry 266, 645–651 (1991).
  7. Stump, W. T. & Hall, K. B. SP6 RNA polymerase efficiently synthesizes RNA from short double-stranded DNA templates. Nucleic Acids Res 21, 5480–5484 (1993).
  8. Latta, A. et al. Levers to optimize the IVT reaction for increased mRNA yield. (2023).
  9. Gurevich, V. V., Pokrovskaya, I. D., Obukhova, T. A. & Zozulya, S. A. Preparative in vitro mRNA synthesis using SP6 and T7 RNA polymerases. Analytical Biochemistry 195, 207–213 (1991).

You might be interested in

...
    ...